IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Trial details
- Registry ID
- NCT05987332
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Darovasertib
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332 | IDEAYA Biosciences | Phase 2, Phase 3 | Active not recruiting | 2027-01-15Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |